Cyclo Therapeutics reports promising NPC1 treatment findings
GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (NASDAQ:CYTH), a clinical-stage biotechnology firm with a market capitalization of $22.15 million, announced positive data from a sub-study of its pivotal ...
Le Lézard1 天
Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPCtm ...
Cyclo Therapeutics, Inc. ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and ...